Call us today 212-583-0100

ENZO Biochem Appoints Marcus A. Conant, M.D. To Its Board Of Directors

FARMINGDALE, NY, July 14, 2004 –Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, today named Marcus A. Conant, M.D., a Professor at the University of California Medical Center, San Francisco, to its Board of Directors.   This brings the number of Board members to eight, including five independent Directors.
Dr. Conant is a graduate of Duke University from which he received his B.S. and M.D. degrees. He was an exchange student at Hammersmith Hospital and held an Elective Fellowship in Biochemistry at the London Hospital, both in London, England.  He has been the recipient of numerous awards, and has served as a member of or consultant to a broad array of scientific societies and associations, community organizations and government committees.  He has appeared as a lecturer at numerous scientific, community and government meetings and has authored or co-authored more than 70 published professional papers.  
“We are pleased to have Dr. Conant, an eminent physician and scientist, join our Board,” said Elazar Rabbani, Ph.D., Chairman and CEO.  “Dr. Conant is an individual of special achievement in the field of medicine and science. Over the past years, Dr. Conant has collaborated with Enzo on issues relating to clinical studies and other scientific matters. His training, experience and his distinguished professional standing in the medical community and elsewhere will be of important value as Enzo moves forward in the development of its numerous clinical therapeutic programs.”
“I am delighted to join the Enzo Board,” said Dr. Conant.   “The executives and scientists at the Company with whom it has been my privilege to work have impressed me with their dedication, determination and accomplishments.   Enzo is a unique biotech company, in which science and technology are extraordinarily advanced and highly promising, in my view, and it is a true pleasure to have this opportunity to contribute to the Company’s future development and growth.”
Dr. Conant served as principal investigator for Enzo’s Phase I clinical trial of its proprietary gene medicine for HIV-1 infection.  He is currently a Clinical Professor at University of California San Francisco (UCSF) Medical Center. He has been on the faculty of UCSF since 1967, having previously completed five years service as a Flight Medical Officer with the U.S. Air Force and Air Force Reserve.   In addition to his scientific work, Dr. Conant currently serves as Chairman of the Board of the Conant Foundation, an HIV/AIDS education and research foundation based in San Francisco.
About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.  The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with over 200 patents worldwide, are sold to the life sciences market throughout the world.  The Company’s therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn’s Disease.  The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes.  For more information visit our website  
Except for historical information, the matters discussed in this news release may be considered ”forward‑looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward‑looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.  The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.